Updated on 27 December 2012
Mr Herbert Vongpusanachai, managing director, DHL Express, Singapore
Mr Herbert Vongpusanachai has spent almost a decade managing Asian logistics market through DHL and has earned in-depth experience of the trends in Singapore, Cambodia, Laos, Myanmar and Thailand. Over the past five years, the respective markets under his care have seen significant growth in business volume and profitability.
In an interview with BioSpectrum, Mr Vongpusanachai shares crucial challenges that a logistic company has to face when serving the pharmaceutical industry for shipment of complex biopharmaceutical drugs.
From manufacturing site to the delivery spot, what is the most crucial phase of the shipment? What are the challenges involved?
The life sciences and healthcare industry is ever-changing and has to take into consideration numerous external factors. A key challenge for most pharmaceutical companies and logistics providers would be the adherence to changes and varied regulations across countries.
The constantly evolving regulatory framework in countries such as India and China as well as timely approvals from the US FDA to regulate the import of a particular product will have an impact on the market. In addition, poor transport infrastructure and limited road networks in some countries also affect the time taken for temperature or time critical products from reaching the final destination.
What are DHL's strategies in handling regulatory requirements of different countries?
Running an efficient supply chain is crucial in the life sciences and healthcare industry as it involves knowledge and expertise in handling complexities and specific regulatory requirements across multiple markets. We have a dedicated customs and regulatory affairs division in Asia Pacific that is experienced to handle the unique, stringent and diverse import and export regulatory requirements of biopharmaceutical goods within our network.